[Hormonal contraception using depot preparations].
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D001777:Blood Coagulation / Q000187:drug effects; D050260:Carbohydrate Metabolism; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D016912:Levonorgestrel; D008099:Liver / Q000187:drug effects; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D009369:Neoplasms / Q000139:chemically induced; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives; D009644:Norgestrel / Q000008:administration & dosage; D011247:Pregnancy; D012306:Risk
D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D009644:Norgestrel; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; C024319:norethindrone enanthate; D009640:Norethindrone
Hormonale Kontrazeption mit Depotpräparaten.